BRCA2 reversion mutation confers resistance to olaparib in breast cancer

Key Clinical Message A rare missense mutation was identified as a reversion mutation using cancer genomic profiling and a suspected mechanism underlying resistance to olaparib in breast cancer. Abstract A 34‐year‐old woman with breast cancer and BRCA2: p.Gln3047Ter was treated with olaparib. After t...

وصف كامل

التفاصيل البيبلوغرافية
الحاوية / القاعدة:Clinical Case Reports
المؤلفون الرئيسيون: Shinya Yamamoto, Kei Kawashima, Yoshie Fujiwara, Shoko Adachi, Kazutaka Narui, Chiaki Hosaka, Rina Takahashi, Sho Tsuyuki, Makoto Sugimori, Miki Tanoshima, Mahato Sasamoto, Masanori Oshi, Akimitsu Yamada, Chikara Kunisaki, Itaru Endo
التنسيق: مقال
اللغة:الإنجليزية
منشور في: Wiley 2023-06-01
الموضوعات:
BRCA
breast neoplasms
genomics
olaparib
الوصول للمادة أونلاين:https://doi.org/10.1002/ccr3.7537

الانترنت

https://doi.org/10.1002/ccr3.7537

مواد مشابهة